A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus

Trial Profile

A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Lixisenatide; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LixiLan-O
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Sep 2017 Results of an exploratory analysis comparing efficacy of simultaneous administration of iGlarLixi in LixiLan-O ( N =469) trial versus sequential administration of insulin glargine followed by addition of lixisenatide in GetGoal Duo-1 ( N =223) trial, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
    • 15 Sep 2017 Results assessing the impact of lixisenatide dose range on glycaemic outcomes in three studies (ACT6011, DRI6012 and LixiLan-O), presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 15 Sep 2017 Results of a post-hoc analysis assessing frequency and timing of gastrointestinal adverse events in patients from two trials (LixiLan-O and LixiLan-L) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top